Reduction of relapse risk through incorporation of novel biologic agents following reduced intensity haploidentical donor transplant for acute myeloid leukemia
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG1HL109526
- Recipient
-
Northside Hospital, Inc. UEI N7LEL48NL6X8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $642,755
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Atlanta, GA 30342, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$152,051 | |
| Amendment | -$153,075 | |
| Amendment | -$31,087 | |
| Amendment | $152,051 | |
| Amendment | -$91,957 | |
| Amendment | $153,075 | |
| Amendment | $154,100 | |
| Amendment | $155,199 | |
| Amendment | $156,263 | |
| Amendment | $149,563 | |
| Amendment | $0 | |
| Original award | $150,674 |
Show all 12
Quick answers
Who received award UG1HL109526?
UG1HL109526 was awarded to Northside Hospital, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on July 28, 2017.
How much is award UG1HL109526 worth?
$642,755 has been obligated on UG1HL109526.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award